P251: XLH molecular diagnoses and the PHEX gene variant landscape: Sponsored hypophosphatemia gene panel testing findings from 2019 vs 2022

P251: XLH molecular diagnoses and the PHEX gene variant landscape: Sponsored hypophosphatemia gene panel testing findings from 2019 vs 2022

Bibliographic Details
Main Authors:	Nicole Miller, Omid Japalaghi, Eric Rush, Kathryn Dahir, Prameela Ramesan, Heather McLaughlin
Format:	Article
Language:	English
Published:	Elsevier 2023-01-01
Series:	Genetics in Medicine Open
Online Access:	http://www.sciencedirect.com/science/article/pii/S2949774423002790

Similar Items

X-linked hypophosphatemia (XLH): Mutations compromising PHEX structure reflect a severe phenotype
by: Whyte, M, et al.
Published: (1999)

X-linked hypophosphatemia attributable to pseudoexons of the PHEX gene.
by: Christie, P, et al.
Published: (2001)

Mutational analysis of PHEX gene in X-linked hypophosphatemia.
by: Dixon, P, et al.
Published: (1998)

P276: Long-chain fatty acid oxidation disorder genotypes, clinical signs and symptoms, and newborn screening history from a gene panel sponsored program
by: Vanessa Rangel Miller, et al.
Published: (2023-01-01)

PHEX<sup>L222P</sup> Mutation Increases <i>Phex</i> Expression in a New ENU Mouse Model for XLH Disease
by: Carole El Hakam, et al.
Published: (2022-07-01)

Sclerostin antibody improves alveolar bone quality in the Hyp mouse model of X-linked hypophosphatemia (XLH)
by: Kelsey A. Carpenter, et al.
Published: (2023-10-01)

Dental health of pediatric patients with X-linked hypophosphatemia (XLH) after three years of burosumab therapy
by: Rafi Brener, et al.
Published: (2022-08-01)

Clinical Evidence for the Benefits of Burosumab Therapy for X-Linked Hypophosphatemia (XLH) and Other Conditions in Adults and Children
by: Aaron Schindeler, et al.
Published: (2020-05-01)

Body composition and cardiometabolic health of pediatric patients with X-linked hypophosphatemia (XLH) under burosumab therapy
by: Avivit Brener, et al.
Published: (2021-03-01)

Clinical and genetic characteristics of 15 families with hereditary hypophosphatemia: Novel Mutations in PHEX and SLC34A3.
by: Sezer Acar, et al.
Published: (2018-01-01)

Pathogenic Variants of the <i>PHEX</i> Gene
by: Yasuhisa Ohata, et al.
Published: (2022-08-01)

Mutation in Phex gene predisposes BALB/c-Phex(Hyp-Duk)/Y mice to otitis media.
by: Fengchan Han, et al.
Published: (2012-01-01)

The International X-Linked Hypophosphatemia (XLH) Registry: first interim analysis of baseline demographic, genetic and clinical data
by: Gema Ariceta, et al.
Published: (2023-09-01)

Real‐world data of Brazilian adults with X‐linked hypophosphatemia (XLH) treated with burosumab and comparison with other worldwide cohorts
by: Maria Helena Vaisbich, et al.
Published: (2024-02-01)

Persistent Lower Limb Deformities Despite Amelioration of Rickets in X-Linked Hypophosphatemia (XLH) - A Prospective Observational Study
by: Gabriel T. Mindler, et al.
Published: (2022-03-01)

X-linked hypophosphataemic rickets due to pseudo-exons of the PHEX gene.
by: Christie, P, et al.
Published: (2000)

Impaired 1,25 dihydroxyvitamin D3 action and hypophosphatemia underlie the altered lacuno-canalicular remodeling observed in the Hyp mouse model of XLH.
by: Ye Yuan, et al.
Published: (2021-01-01)

P030: Diverse genetic findings, clinical signs, and newborn screening history from a long-chain fatty acid oxidation disorders gene panel sponsored program
by: Nicole Miller, et al.
Published: (2024-01-01)

Hiding in plain sight: Gene panel and genetic markers reveal 26-year undiagnosed tumor-induced osteomalacia of the rib concurrently misdiagnosed as X-linked hypophosphatemia
by: Juan M. Colazo, BSc, et al.
Published: (2021-06-01)

XLH Matters 2022: Insights and recommendations to improve outcomes for people living with X-linked hypophosphataemia (XLH)
by: Lothar Seefried, et al.
Published: (2023-10-01)

Identification of two novel mutations in the PHEX gene in Chinese patients with hypophosphatemic rickets/osteomalacia.
by: Hua Yue, et al.
Published: (2014-01-01)

Combined treatment by burosumab and a calcimimetic can ameliorate hypophosphatemia due to excessive actions of FGF23 and PTH in adult XLH with tertiary hyperparathyroidism: A case report
by: Yuichi Takashi, et al.
Published: (2022-12-01)

The recommended starting dose of 0.4mg/kg burosumab is insufficient for most children with X-linked hypophosphatemia (XLH) - Results from the first treated patients in Sweden
by: Sigrun Hallgrimsdottir, et al.
Published: (2020-10-01)

FURTHER LOCALIZATION OF THE GENE FOR X-LINKED HYPOPHOSPHATEMIA
by: Read, A, et al.
Published: (1987)

PHEX Gene Mutation in a Patient with X-Linked Hypophosphatemic Rickets in a Developing Country
by: Forero-Delgadillo JM, et al.
Published: (2020-02-01)

USM RESEARCHER EXCELS AT I-PHEX 2016
by: MPRC, Pusat Media & Perhubungan Awam
Published: (2016)

Long-term safety in adults with X-linked Hypophosphatemia (XLH) treated with Burosumab, a fully human monoclonal antibody against FGF23: Final results of a phase 3 trial
by: Peter Kamenický, et al.
Published: (2020-10-01)

USM RANGKUL KEJAYAAN DI I-PHEX 2016
by: MPRC, Pusat Media & Perhubungan Awam
Published: (2016)

UMP rangkul tiga pingat pada I-PHEX
by: UMP, .
Published: (2015)

The ankle in XLH: Reduced motion, power and quality of life
by: Celine Akta, et al.
Published: (2023-03-01)

Mycobacterium leprae downregulates the expression of PHEX in Schwann cells and osteoblasts
by: Sandra R Boiça Silva, et al.
Published: (2010-08-01)

Expression and cloning of the human X-linked hypophosphatemia gene cDNA.
by: Grieff, M, et al.
Published: (1997)

Pirates of the Cyber Seas: Are State-Sponsored Hackers Modern-Day Privateers?
by: Josephine Helen Dwan, et al.
Published: (2022-05-01)

Young XLH Patients-Reported Experience with a Supportive Care Program
by: Rothenbuhler A, et al.
Published: (2023-06-01)

The contribution of a novel PHEX gene mutation to X-linked hypophosphatemic rickets: a case report and an analysis of the gene mutation dosage effect in a rat model
by: Xiaoming Chen, et al.
Published: (2023-12-01)

Metabolomics of Plasma in XLH Patients with Arterial Hypertension: New Insights into the Underlying Mechanisms
by: Luis Carlos López-Romero, et al.
Published: (2024-03-01)

Change in patient-reported outcomes of XLH registry participants in the UK: a longitudinal study
by: Cole, S, et al.
Published: (2021)

Wnt pathway inhibitors are upregulated in XLH dental pulp cells in response to odontogenic differentiation
by: Elizabeth Guirado, et al.
Published: (2023-02-01)

Anticipated effects of burosumab treatment on long-term clinical sequelae in XLH: expert perspectives
by: Lothar Seefried, et al.
Published: (2023-07-01)

Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment
by: Karine Briot, et al.
Published: (2023-02-01)